Skip to main content
Shanghai Junshi Biosciences Co.,Ltd. logo

Shanghai Junshi Biosciences Co.,Ltd. — Investor Relations & Filings

Ticker · 688180 ISIN · CNE1000041Z1 LEI · 300300L36FLCKN0WXW06 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,065 across all filing types
Latest filing 2025-08-26 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688180

About Shanghai Junshi Biosciences Co.,Ltd.

https://www.junshipharma.com/

Shanghai Junshi Biosciences Co., Ltd. is an innovation-driven biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies. The company maintains a diverse pipeline targeting oncology, immunology, metabolic disorders, neurological diseases, and infectious diseases. A pioneer in its field, it developed Toripalimab, the first domestically produced anti-PD-1 monoclonal antibody to receive marketing approval in its home market. Its integrated R&D platform encompasses the entire drug development lifecycle, from initial discovery and clinical evaluation to large-scale manufacturing and global commercialization. The company collaborates with international partners to expand the reach of its innovative biologics, including monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates, aiming to provide effective and affordable treatment options for patients globally.

Recent filings

Filing Released Lang Actions
君实生物第四届监事会第八次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of resolutions passed at the eighth meeting of the fourth Supervisory Board of Shanghai Junshi Biosciences Co., Ltd. It includes approval of the 2025 semi-annual report and related matters, but does not contain the report itself. It references that the full semi-annual report and related disclosures are published separately on the Shanghai Stock Exchange and Hong Kong Stock Exchange websites. The document also discusses the cancellation of the Supervisory Board and related governance changes, which will be submitted to the shareholders' meeting. The document length is short (1640 characters) and primarily serves as a meeting resolution announcement rather than the actual semi-annual report or detailed financial data. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a formal regulatory announcement of meeting resolutions and related governance updates, not the report itself or a detailed financial report.
2025-08-26 Chinese
君实生物2025年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2025 年半年度报告摘要' which translates to '2025 Semi-Annual Report Summary'. It contains detailed financial data for the half-year period, including total assets, net profit, revenue, and shareholder information. The document explicitly states it is a summary of the half-year report and advises investors to read the full half-year report on the official website. The document length is 3959 characters, which is relatively short but contains substantive financial data and analysis, including financial metrics and shareholder information. The document is not merely an announcement or a certification but contains actual financial data and management discussion. Therefore, it fits the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year, containing actual financial statements and substantive financial data and analysis. Hence, the correct classification is IR with high confidence. H1 2025
2025-08-26 Chinese
君实生物董事会战略委员会工作细则（2025年8月修订稿）
Governance Information Classification · 95% confidence The document is titled as the "Board of Directors Strategic Committee Working Rules" of Shanghai Junshi Biosciences Co., Ltd. It details the composition, responsibilities, meeting procedures, and governance of the board's strategic committee. There is no financial data, no mention of financial results, no shareholder voting results, no legal proceedings, no capital changes, or any other typical financial or regulatory filing content. The document is a governance-related internal rules document describing the board committee's structure and functions. This fits the definition of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length is 3306 characters, which is consistent with a detailed governance document rather than a brief announcement or a full annual report. Therefore, the classification is CGR with high confidence.
2025-08-26 Chinese
君实生物董事会审计委员会工作细则（2025年8月修订稿）
Governance Information Classification · 95% confidence The document is titled "董事会审计委员会工作细则" which translates to "Board Audit Committee Working Rules". It details the composition, responsibilities, procedures, and governance of the audit committee within the board of directors of the company. The content focuses on internal governance, audit committee duties, meeting rules, and compliance with relevant laws and listing rules. There are no financial statements, earnings data, or direct financial results presented. The document is a governance-related internal rules document rather than a financial report or announcement. Therefore, it fits best under Governance Information (CGR).
2025-08-26 Chinese
君实生物2025年半年度募集资金存放与实际使用情况专项报告
Interim / Quarterly Report Classification · 95% confidence The document is a detailed report on the use and management of funds raised by Shanghai Junshi Biosciences through initial public offering and subsequent private placements. It includes specifics on amounts raised, usage, balances, investment projects, changes in project funding, and compliance with regulatory requirements. The document references regulatory rules related to fundraising and fund management, and it is titled as a "2025 Semi-Annual Special Report on the Deposit and Actual Use of Raised Funds." It contains substantive financial data and analysis for a half-year period (2025 first half). This matches the characteristics of an Interim / Quarterly Report (IR), as it is a comprehensive financial report for a period shorter than a full fiscal year, with detailed financial data and explanations. It is not an announcement of a report, nor a certification or a brief summary. Therefore, the correct classification is IR with high confidence. H1 2025
2025-08-26 Chinese
君实生物股东会议事规则（2025年8月修订稿）
Governance Information Classification · 95% confidence The document is titled "股东会议事规则" which translates to "Shareholders Meeting Rules" or "Rules of Procedure for Shareholders' Meetings". It contains detailed procedural rules for convening, conducting, and voting in shareholders' meetings, including chapters on general provisions, meeting convocations, proposals, voting, resolutions, and records. There is no financial data, earnings information, or report content. It is a governance-related document outlining internal rules and procedures for shareholder meetings. It is not an announcement or a report publication but a formal governance document. Therefore, the most appropriate classification is Governance Information (CGR). The document length (11,898 characters) supports it being a full procedural document rather than a brief announcement.
2025-08-26 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.